At a glance
ClinicalIndex Comparison RecordN/ACompleted· 45 enrolled
Drug / intervention
Bellovac ABT +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open , Prospective, Randomized, Parallel Group Study to Investigate Whether Postoperatively Collected and Transfused Autologous Whole Blood Improves the Immunological Status in Comparison to Allogenic Blood Transfusion in Patients Undergoing Total Knee Replacement
In Brief
A clinical study evaluating Bellovac ABT and Allogenic Blood Transfusion for Arthroplasty, Replacement, Knee and 2 related conditions. Completed, enrolled 45 participants across 1 site.
Detailed Summary
The primary objective of the study is to compare the immunological status after either autologous blood transfusion as administered by Bellovac® ABT or allogenic blood transfusion, with regards to change in Natural Killer (NK) cell frequency in patients undergoing total knee replacement.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesPoland
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2009
First PostedFeb 2009
Primary CompletionJun 2009
TodayJul 2026
First PostedFeb 9, 2009
Enrollment StartJan 1, 2009
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.4 years ago
Interventions
Bellovac ABTdevice
Bellovac ABT (autologous blood)
Allogenic Blood Transfusionprocedure
Transfusion of allogenic ("bank") blood.